Helix BioPharma Corp. (HBP) files for Clinical Trial Application in Germany and UK for Approval of Phase III Efficacy Trial
Helix BioPharma Corp., a biopharmaceutical company developing drug candidates for the prevention and treatment of cancer, has filed a clinical trial application (CTA) in both Germany and the United Kingdom, with the Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM) and the Medicines and Healthcare Regulatory Authority (MHRA) respectively. The company is seeking approval to perform its planned European phase III efficacy trial of Topical Interferon Alpha-2b in patients with low-grade cervical lesions. Topical Interferon Alpha-2b is the company's most advanced product in development. By incorporating Helix’s proprietary Biphasix™ drug delivery technology, Topical Interferon Alpha-2b is designed to offer a superior method…